Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 2358 • 2019 ACR/ARP Annual Meeting
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Margaux MALAURIE¹, Arnaud Constantin ², Yannick Degboé ¹, Adeline Ruyssen-Witrand ³ and Thomas Barnetche ⁴, ¹CHU TOULOUSE, TOULOUSE, France, ²CHU TOUOUSE, TOULOUSE, France, ³Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ⁴FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France
Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis…
Abstract Number: 59 • 2019 ACR/ARP Annual Meeting
Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Julie Di Paolo¹, Bryan Downie ², Amy Meng ³, Nevena Mollova ³, Yuanjiang Yu ³ and Pei Han ³, ¹Gilead Sciences, Foster City, CA, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway have demonstrated efficacy in immune-mediated diseases and haves been identified as therapeutic…
Abstract Number: 2393 • 2019 ACR/ARP Annual Meeting
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz ², Maryam Sadiq ³, Muhammad Salick ⁴, Yahya Nomaan ⁵, Nusrum Iqbal ⁶, Sandipan Bhattacharjee ⁷, Lary Prokop ⁸ and C. Kent Kwoh ⁷, ¹University of Arizona College of Medicine, Tucson, AZ, ²Mayo Hospital Rochester, Rochester, MN, ³Nishtar Medical College, University of Health Sciences, Lahore, Albany, NY, ⁴Albany Medical Center, Albany, NY, ⁵Phoenix Children's Hospital, Phoenix, AZ, ⁶St Joseph's Hospital, Tucson AZ, Tucson, AZ, ⁷University of Arizona, Tucson, AZ, ⁸Mayo Clinic, Rochestor, MN
Background/Purpose: Importance The efficacy of Janus kinase (JAK) inhibitors is well established across a range of diseases. However, there is a major concern regarding the potential risk of an increased…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Christian S. Thudium¹, Anne C. Bay-Jensen¹, Suntara Cahya², Ernst R. Dow², Morten A. Karsdal¹, Alisa E. Koch², Wenling Zhang² and Robert J. Benschop², ¹Nordic Bioscience, Herlev, Denmark, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 2065 • 2018 ACR/ARHP Annual Meeting
Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
Yukiko Maeda¹, Zheni Stavre¹, Tingting Huang², Catherine Manning², Bryant Shaughn³, Michael Macoritto³, Deborah Hyland³, Wendy Waegell³ and Ellen M. Gravallese⁴, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, worcester, MA, ³Abbvie Bioresearch Center, worcester, MA, ⁴Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) results in significant pain and loss of function due to inflammation and resulting enthesial/periosteal bone formation. Inhibition of the Janus kinase (JAK)/STAT…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Josef S. Smolen¹, Stanley Cohen², Paul Emery³, William F C Rigby⁴, Yoshiya Tanaka⁵, Ying Zhang⁶, Alan Friedman⁶, Ahmed A. Othman⁶, Heidi S. Camp⁶ and Aileen L. Pangan⁶, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Metroplex Clinical Research Center, Dallas, TX, ³Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, ⁴Dartmouth College, Hanover, NH, ⁵Univ of Occupational and Environmental Health, Kitakyushu, Japan, ⁶AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].